Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS‐CoV‐2 infection
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Yuexiu Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Measles virus (MeV) has been an excellent vector platform for delivering vaccines against many pathogens because of its high safety and efficacy, and induction of long‐lived immunity. Early in the COVID‐19 pandemic, a recombinant MeV (rMeV) expressing the prefusion full‐length spike protein stabilized by two prolines (TMV‐083) was developed and tested in phase 1 and 1/2 clinical trials but was discontinued because of insufficient immunogenicity and a low seroconversion rate in adults. Here, we compared the immunogenicity of rMeV expressing a soluble prefusion spike (preS) protein stabilized by two prolines (rMeV‐preS‐2P) with a rMeV expressing a soluble preS protein stabilized by six prolines (rMeV‐preS‐6P). We found that rMeV‐preS‐6P expressed approximately five times more preS than rMeV‐preS‐2P in cell culture. Importantly, rMeV‐preS‐6P induced 30‐60 and six times more serum immunoglobulin G and neutralizing antibody than rMeV‐preS‐2P, respectively, in IFNAR −/− mice. IFNAR −/− mice immunized with rMeV‐preS‐6P were completely protected from challenge with a mouse‐adapted SARS‐CoV‐2, whereas those immunized with rMeV‐preS‐2P were partially protected. In addition, hamsters immunized with rMeV‐preS‐6P were completely protected from the challenge with a Delta variant of SARS‐CoV‐2. Our results demonstrate that rMeV‐preS‐6P is significantly more efficacious than rMeV‐preS‐2P, highlighting the value of using preS‐6P as the antigen for developing vaccines against SARS‐CoV‐2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
- Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Infectious Disease Institute, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Jianrong Li
Förderung
- NIAID NIH HHS
Zitieren
APA
Zhang, Y., Lu, M., Thongpan, I., Xu, J., Kc, M., Dravid, P., Trivedi, S., Sharma, H., Liang, X., Kapoor, A., Peeples, M. E., & Li, J. (2023). Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS‐CoV‐2 infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.28687
Vancouver
Zhang Y, Lu M, Thongpan I, Xu J, Kc M, Dravid P, et al. Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS‐CoV‐2 infection. Journal of Medical Virology. 2023. doi:10.1002/jmv.28687
BibTeX
@article{Zhang2023,
author = {Zhang, Yuexiu and Lu, Mijia and Thongpan, Ilada and Xu, Jiayu and Kc, Mahesh and Dravid, Piyush and Trivedi, Sheetal and Sharma, Himanshu and Liang, Xueya and Kapoor, Amit and Peeples, Mark E and Li, Jianrong},
title = {Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS‐CoV‐2 infection},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28687}
}
EUVIMED